Disclosure SB has received travel support from Bristol Myers Squibb (BMS) and travel support, consulting fees and research funding from Takeda; is shareholder and CEO of Liqomics; BCÖ honoraria (institutional) for lectures and advisory boards: BMS, Merck Sharp & Dohme, Merck, Roche, Ipsen. SOP was a member of the EU Expert group “Gendered Innovations 2” (2018-2020) and received speakers honoraria from Pfizer. ADW has received honoraria for lectures and advisory boards from Lilly, Merck Sharp & Dohme, BMS, Pfizer, Merck, Servier, Shire, Bayer, Taiho, Pierre Fabre, Dragonfly Pharmaceuticals, Daiichi-Sankyo, all paid to her institution and reimbursed in part. In addition, she received travel support from Ipsen, MSD, abbvie, Sanofi-Aventis, AstraZeneca, Janssen. She is coordinating investigator of EORTC-trial 1203, which is supported by an educational grant from Roche to EORTC; OM has received consultancy fees from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Eli Lilly, Ipsen, Lundbeck, Merck Sharpe & Dohme, Pfizer, Roche, Servier, and Vifor Pharma; RHAV has received a research grant from Bristol Myers Squibb paid to institution; JBH performed advisory work for which NKI was reimbursed for: Achilles Tx, BioNTech, BMS, Immunocore, Instil Bio, Iovance Bio, Ipsen, Merck Serono, MSD, Molecular Partners, Novartis, Pfizer, PokeAcel, Roche, Sanofi, T-Knife, and for Neogene Tx for which he is was personally reimbursed. Through JBH NKI received research grants from Asher Bio, Amgen, BioNTech, BMS, MSD, Neogene Tx, Novartis. JBH owns stock options in Neogene Tx. All other authors have declared no conflicts of interest.